Education
About Us
Working with TipRanks
Follow Us
Neurosense Therapeutics Ltd. (NRSN)
NASDAQ:NRSN
NRSN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.51 - $2.29
Previous CloseN/A
Volume34.16K
Average Volume (3M)150.25K
Market Cap
$25.73M
Enterprise Value$24.80M
Total Cash (Recent Filing)-$895.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.10
Next Earnings
Mar 19, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.70
Shares Outstanding23,228,941
10 Day Avg. Volume121,817
30 Day Avg. Volume150,247
Standard Deviation0.47
R-Squared0.02
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-255.64
Enterprise Value/Ebitda-1.93
Forecast
1Y Price Target
$7.50Price Target Upside575.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Neurosense Therapeutics Ltd. News
PremiumCompany Announcements
NeuroSense Therapeutics Reports Key Progress and Financials
PremiumCompany Announcements
NeuroSense Regains Nasdaq Compliance, Strengthens Position for ALS Treatment
PremiumCompany Announcements
NeuroSense Partners with Pharma Giant to Propel ALS Drug PrimeC
PremiumCompany Announcements
NeuroSense Advances ALS Treatment with PrimeC, Boosts Financial Position---
Bulls Say, Bears Say
Bulls Say
Canadian Market PotentialNeuroSense announced plans to pursue early commercialization of PrimeC for ALS in Canada, potentially allowing revenue and cash flow before U.S. approval.
Bears Say
Financial ConstraintsCapital constraints, including “baby shelf” limitations, make it difficult to raise sufficient capital to fully finance the Phase 3 trial.
Regulatory ChallengesShares are downgraded to Hold due to the unlikelihood of pursuing an Accelerated Approval pathway in the U.S. for PrimeC.
---
Ownership Overview
26.88%
Insiders
0.05% Mutual Funds
0.30% Other Institutional Investors
72.76% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
NRSN FAQ
What was Neurosense Therapeutics Ltd.’s price range in the past 12 months?
Neurosense Therapeutics Ltd. lowest stock price was $0.51 and its highest was $2.29 in the past 12 months.
What is Neurosense Therapeutics Ltd.’s market cap?
Neurosense Therapeutics Ltd.’s market cap is $25.73M.
When is Neurosense Therapeutics Ltd.’s upcoming earnings report date?
Neurosense Therapeutics Ltd.’s upcoming earnings report date is Mar 19, 2025 which is in 15 days.
How were Neurosense Therapeutics Ltd.’s earnings last quarter?
Neurosense Therapeutics Ltd. released its earnings results on Dec 18, 2024. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.01.
Is Neurosense Therapeutics Ltd. overvalued?
According to Wall Street analysts Neurosense Therapeutics Ltd.’s price is currently Undervalued.
Does Neurosense Therapeutics Ltd. pay dividends?
Neurosense Therapeutics Ltd. does not currently pay dividends.
What is Neurosense Therapeutics Ltd.’s EPS estimate?
Neurosense Therapeutics Ltd.’s EPS estimate is -0.12.
How many shares outstanding does Neurosense Therapeutics Ltd. have?
Neurosense Therapeutics Ltd. has 23,228,941 shares outstanding.
What happened to Neurosense Therapeutics Ltd.’s price movement after its last earnings report?
Neurosense Therapeutics Ltd. reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went up 4.587%.
Which hedge fund is a major shareholder of Neurosense Therapeutics Ltd.?
Currently, no hedge funds are holding shares in NRSN
---
Company Description
Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
---
NRSN Stock 12 Month Forecast
Average Price Target
$7.50
▲(575.68% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Neurocrine
―
SAGE Therapeutics
―
Axsome Therapeutics
―
Bioxcel Therapeutics
―
Best Analysts Covering NRSN
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-24.90%
reiterated a buy rating 28 days ago
Copying James Molloy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -24.90% per trade.
---